GENETIC FACTORS IMPORTANCE IN PARKINSON DISEASE
Keywords:
Parkinson disease, genetics, neurodegeneration, α-synuclein, SNCA, LRRK2, PARK2, PINK1, DJ-1, GBA1, mitochondrial dysfunction, oxidative stress, lysosomal dysfunction, personalized medicine, gene mutations, dopaminergic neurons, Lewy bodies, genome-wide association studies, precision therapyAbstract
Parkinson disease is the second most common neurodegenerative disorder after Alzheimer disease and represents a major global health challenge. Traditionally considered a sporadic disorder primarily associated with aging and environmental exposure, Parkinson disease is now increasingly recognized as having a strong genetic component. Advances in molecular genetics and genomic technologies have identified numerous genes and genetic variants associated with disease susceptibility, progression, and clinical heterogeneity. Mutations in genes such as SNCA, LRRK2, PARK2, PINK1, DJ-1, and GBA1 have significantly contributed to understanding the molecular pathogenesis of Parkinson disease. These discoveries have revealed critical mechanisms including α-synuclein aggregation, mitochondrial dysfunction, oxidative stress, lysosomal impairment, and neuroinflammation. Genetic studies have also facilitated the development of targeted therapies and personalized medicine approaches.
References
1. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015.
2. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nature Reviews Disease Primers. 2017.
3. Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson’s disease. Movement Disorders. 2013.
4. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurology. 2020.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal